Cerulean Pharma Inc. (CERU) Trading 3.8% Higher
Shares of Cerulean Pharma Inc. (NASDAQ:CERU) traded up 3.8% on Friday . The company traded as high as $3.07 and last traded at $3.02, with a volume of 135,267 shares. The stock had previously closed at $2.91.
A number of analysts have recently weighed in on the stock. Canaccord Genuity restated a “buy” rating on shares of Cerulean Pharma in a report on Tuesday, May 3rd. Leerink Swann restated a “buy” rating on shares of Cerulean Pharma in a report on Sunday, June 26th. Zacks Investment Research downgraded shares of Cerulean Pharma from a “buy” rating to a “hold” rating in a report on Wednesday. Janney Montgomery Scott assumed coverage on shares of Cerulean Pharma in a report on Wednesday, June 1st. They issued a “buy” rating on the stock. Finally, Wedbush restated an “outperform” rating and issued a $9.00 target price on shares of Cerulean Pharma in a report on Tuesday, April 19th. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $9.25.
The company’s market capitalization is $81.33 million. The stock’s 50 day moving average is $2.52 and its 200-day moving average is $2.52.
Cerulean Pharma (NASDAQ:CERU) last posted its quarterly earnings data on Thursday, August 4th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.48) by $0.08. Equities analysts anticipate that Cerulean Pharma Inc. will post ($1.64) earnings per share for the current year.
Cerulean Pharma Inc is a clinical-stage, oncology-focused company. The Company applies its Dynamic Tumor Targeting platform to develop differentiated therapies. Its platform utilizes nanoparticle-drug conjugates (NDCs), which consist of polymers that are covalently linked to anti-cancer therapeutics or payloads.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.